| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by date.
Page 7: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1801 | 16 | 47 | 1921 2001 JAN [15] DRUGS OF THE FUTURE 26(1):100-103 [Anon] Thalidomide - Synovir (R) - Thalomid (R) - Talizer (R) - Oncolytic treatment of IBD antiarthritic treatment of leprosy | 0 | 0 |
| 1802 | 13 | 23 | 1949 2001 JAN [15] INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B | 5 | 8 |
| 1803 | 4 | 10 | 1964 2001 JAN 15 JOURNAL OF INFECTIOUS DISEASES 183(2):343-346 Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C; Natl Inst Allergy Infect Dis AIDS Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers | 1 | 3 |
| 1804 | 9 | 23 | 1966 2001 JAN [15] JOURNAL OF NEURO-ONCOLOGY 51(1):41-45 Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M Thalidomide as an anti-angiogenic agent in relapsed gliomas | 10 | 20 |
| 1805 | 6 | 15 | 1994 2001 JAN-FEB [JAN 15] OPHTHALMOLOGICA 215(1):70-73 Parentin F; Da Pozzo S; Lepore L; Perissutti P Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child | 2 | 2 |
| 1806 | 16 | 18 | 2001 2001 JAN [15] REVUE DE MEDECINE INTERNE 22(1):5-7 Grosbois B; Duguet C Thalidomide: the revival | 2 | 4 |
| 1807 | 32 | 52 | 2014 2001 JAN [15] TOXICOLOGICAL SCIENCES 59(1):160-168 Teo SK; Evans MG; Brockman MJ; Ehrhart J; Morgan JM; Stirling DI; Thomas SD Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs | 4 | 4 |
| 1808 | 5 | 7 | 2003 2001 JAN 22 SCIENTIST 15(2):1-+ Lewis R The return of thalidomide | 0 | 1 |
| 1809 | 3 | 7 | 1806 2001 FEB [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(2):148-149 Esteve E; Legac E Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide | 4 | 4 |
| 1810 | 9 | 12 | 1884 2001 FEB [15] BRITISH JOURNAL OF DERMATOLOGY 144(2):227-228 Allen BR Thalidomide | 4 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1811 | 30 | 32 | 1885 2001 FEB [15] BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |
| 1812 | 11 | 18 | 1969 2001 FEB [15] JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(2):178-181 Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results | 10 | 17 |
| 1813 | 10 | 51 | 1899 2001 FEB 26 CANCER LETTERS 163(2):191-200 Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma | 4 | 10 |
| 1814 | 0 | 0 | 1926 2001 MAR 7 FASEB JOURNAL 15(4):A556-A556 Jajeh A; Boulos B; Youakim J; Ali M; Woynarowsky A In vitro reduction of accelerated apoptosis of neutrophils in blood drawn from an HIV positive subject with Thalidomide. | 0 | 0 |
| 1815 | 53 | 140 | 1919 2001 20010309-15:04:09 [MAR 09] DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 13 |
| 1816 | 3 | 4 | 2012 2001 MAR 10 SWISS MEDICAL WEEKLY 131(9-10):133-133 Trojan A; Anagnostara A; Fost L Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma | 2 | 2 |
| 1817 | 0 | 0 | 1879 2001 MAR [15] BONE MARROW TRANSPLANTATION 27:S251-S252 Hus M; Dmoszynska A; Legiec W; Jawniak D; Soroka-Wojtaszko M; Manko J Thalidomide as a preparative regimen and late stem cell transplantation in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| 1818 | 0 | 0 | 1932 2001 MAR [15] GUT 48:A48-A48 Khan ZH; Cole AT; Macdonald I; Pye D; Simpson L; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancer | 0 | 0 |
| 1819 | 0 | 0 | 1933 2001 MAR [15] GUT 48:A67-A68 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
| 1820 | 0 | 0 | 1934 2001 MAR [15] GUT 48:A89-A90 Trebble T; Johns T; Duncan HD; Goggin PM An open trial of thalidomide in refractory Crohn's colitis | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1821 | 0 | 0 | 1951 2001 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 42(4):S233-S233 Maguire MG; Fine SL; Maguire AM; D'Amato RJ; Singerman LJ Results of the age-related macular degeneration and thalidomide study (AMDATS). | 0 | 5 |
| 1822 | 27 | 28 | 1970 2001 MAR [15] JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324 Strauss RS; Das FM Thalidomide-induced sensory neuropathy | 2 | 3 |
| 1823 | 0 | 0 | 1974 2001 MAR [15] LEUKEMIA 15(3):491-491 Barlogie D; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 0 |
| 1824 | 0 | 0 | 1988 2001 MAR [15] ONCOLOGY-NEW YORK 15(3):301-301 [Anon] Thalidomide analogs active against multiple myeloma | 0 | 0 |
| 1825 | 9 | 16 | 1996 2001 MAR-APR [MAR 15] PEDIATRIC DERMATOLOGY 18(2):143-145 Brik R; Shamali H; Bergman R Successful thalidomide treatment of severe infantile Behcet disease | 1 | 1 |
| 1826 | 0 | 1 | 1981 2001 MAR 22 NATURE 410(6827):411-412 Dormandy T Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 1827 | 4 | 7 | 1801 2001 APR [15] AMERICAN JOURNAL OF GASTROENTEROLOGY 96(4):1305-1306 Ginsburg PM; Hanan I; Ehrenpreis ED Treatment of severe esophageal Crohn's disease with thalidomide | 8 | 10 |
| 1828 | 8 | 12 | 1803 2001 APR [15] AMERICAN JOURNAL OF HEMATOLOGY 66(4):300-302 Fowler R; Imrie K Thalidomide-associated hepatitis: A case report | 5 | 6 |
| 1829 | 14 | 32 | 1826 2001 APR [15] BIOORGANIC & MEDICINAL CHEMISTRY 9(4):1059-1065 Gutschow M; Hecker T; Thiele A; Hauschildt S; Eger K Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro | 3 | 8 |
| 1830 | 2 | 4 | 1828 2001 APR 15 BLOOD 97(8):2527-2528 Kyrtsonis MC; Kokoris SI; Kontopidou FN; Siakantaris MP; Kittas C; Pangalis GA Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1831 | 8 | 37 | 1897 2001 APR [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(4):319-326 Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac | 2 | 9 |
| 1832 | 0 | 0 | 1928 2001 APR [15] GASTROENTEROLOGY 120(5):A278-A278 Stein DJ; Rafiee P; Taras A; Lamirand TH; Fisher PJ; Ogawa H; Telford GL; Otterson MF; Johnson CP; Binion DG Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). | 0 | 0 |
| 1833 | 0 | 0 | 1929 2001 APR [15] GASTROENTEROLOGY 120(5):A611-A612 Khan ZH; Cole AT; MacDonald I; Pye D; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancers | 0 | 0 |
| 1834 | 0 | 2 | 1935 2001 APR [15] HAEMATOLOGICA 86(4):348-348 [Anon] Thalidomide in the treatment of multiple myeloma | 0 | 0 |
| 1835 | 7 | 27 | 1936 2001 APR [15] HAEMATOLOGICA 86(4):399-403 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma | 24 | 37 |
| 1836 | 5 | 21 | 1937 2001 APR [15] HAEMATOLOGICA 86(4):404-408 Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J; Polish Multiple Myeloma Study Grp Thalidomide treatment of resistant or relapsed multiple myeloma patients | 23 | 35 |
| 1837 | 17 | 33 | 1938 2001 APR [15] HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
| 1838 | 0 | 0 | 1939 2001 APR [15] HAEMATOLOGICA 86(4):448-448 Zappasodi P; Lorenzi A; Corso A Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity | 1 | 1 |
| 1839 | 22 | 36 | 1948 2001 APR [15] INFLAMMATION 25(2):91-96 Belo AV; Ferreira MAND; Bosco AA; Machado RDP; Andrade SP Differential effects of thalidomide on angiogenesis and tumor growth in mice | 0 | 2 |
| 1840 | 0 | 0 | 1963 2001 APR [15] JOURNAL OF HEPATOLOGY 34:18-18 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1841 | 0 | 1 | 1977 2001 APR 15 LIBRARY JOURNAL 126(7):126-126 Kupferberg N Dark remedy: The impact of thalidomide and its revival as a vital medicine. | 0 | 0 |
| 1842 | 0 | 0 | 1989 2001 APR [15] ONCOLOGY-NEW YORK 15(4):493-+ [Anon] Thalidomide studied in a variety of cancers and metabolic disorders | 0 | 0 |
| 1843 | 0 | 0 | 1983 2001 APR 24 NEUROLOGY 56(8):A208-A209 Khella SL; Souayah N; AMDATS Study Grp Thalidomide polyneuropathy: A prospective double-masked placebo-controlled study in an elderly population with age-related macular degeneration | 0 | 0 |
| 1844 | 32 | 42 | 1978 2001 20010503-14:08:37 [MAY 03] LUPUS 10(3):188-192 Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV Update on therapy - thalidomide in the treatment of lupus | 6 | 13 |
| 1845 | 35 | 44 | 1804 2001 MAY [15] AMERICAN JOURNAL OF THE MEDICAL SCIENCES 321(5):321-326 Moraes M; Russo G Thalidomide and its dermatologic uses | 3 | 9 |
| 1846 | 11 | 12 | 1807 2001 MAY [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(5):611-613 Estines O; Revuz J; Wolkenstein P; Bressieux JM; Roujeau JC; Cosnes A Sarcoidosis: thalidomide treatment in ten patients | 5 | 6 |
| 1847 | 5 | 14 | 1813 2001 MAY [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 45(5):1547-1549 Juffermans NP; Verbon A; Schultz MJ; Hack CE; van Deventer SJH; Speelman P; van der Poll T Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens | 2 | 2 |
| 1848 | 1 | 33 | 1825 2001 MAY [15] BIOMEDICAL CHROMATOGRAPHY 15(3):202-206 Duval R; Leveque H; Prigent Y; Aboul-Enein HY Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases | 1 | 4 |
| 1849 | 17 | 41 | 1827 2001 MAY [15] BIOORGANIC & MEDICINAL CHEMISTRY 9(5):1279-1291 Hess S; Akermann MA; Wnendt S; Zwingerberger K; Eger K Synthesis and immunological activity of water-soluble thalidomide prodrugs | 2 | 4 |
| 1850 | 5 | 12 | 1887 2001 MAY [15] BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1851 | 3 | 10 | 1902 2001 MAY [15] CHILDS NERVOUS SYSTEM 17(6):370-372 Schoeman JF; Ravenscroft A; Hartzenberg HB Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess | 5 | 5 |
| 1852 | 3 | 3 | 1905 2001 MAY-JUN [MAY 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 19(3):360-361 Scoville CD Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis | 5 | 5 |
| 1853 | 6 | 6 | 1930 2001 MAY [15] GASTROENTEROLOGY 120(6):1567-1568 Fox MR; Harris A Intractable insomnia after cessation of treatment with thalidomide | 3 | 3 |
| 1854 | 1 | 26 | 1984 2001 MAY-JUN [MAY 15] NEUROTOXICOLOGY AND TERATOLOGY 23(3):255-264 Vorhees CV; Weisenburger WP; Minck DR Neurobehavioral teratogenic effects of thalidomide in rats | 1 | 3 |
| 1855 | 52 | 73 | 1822 2001 20010517-08:31:18 [MAY 17] BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
| 1856 | 0 | 1 | 1987 2001 MAY 17 NEW YORK REVIEW OF BOOKS 48(8):12-15 Horton R Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 1857 | 3 | 3 | 1998 2001 JUN 9 PRESSE MEDICALE 30(20):1008-1009 Pouaha J; Martin S; Trechot P; Truchetet F; Barbaud A; Schmutz JL Thalidomide and thrombosis: three cases | 5 | 5 |
| 1858 | 47 | 67 | 1920 2001 20010613-11:16:17 [JUN 13] DRUGS 61(6):777-787 Bousvaros A; Mueller B Thalidomide in gastrointestinal disorders | 4 | 8 |
| 1859 | 11 | 31 | 1898 2001 JUN [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(6):541-544 Zhou SF; Kestell P; Tingle MD; Ching LM; Paxton JW A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide | 2 | 5 |
| 1860 | 0 | 0 | 1911 2001 JUN [15] CLINICAL LYMPHOMA 2(1):16-17 [Anon] Thalidomide shows promise in previously untreated and refractory multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1861 | 0 | 0 | 1916 2001 JUN [15] DIABETES 50:A473-A473 Bosco A; Lerario AC; Santos RF; Ferreira A; Ursich MJ; Silva ME; Rocha DM; Wajchenberg BL Study of Thalidomide and Rosiglitazone effects on the prevention of diabetic retinopathy of Streptozotocin diabetic rats | 0 | 0 |
| 1862 | 2 | 5 | 1956 2001 JUN [15] JOURNAL OF CHEMICAL EDUCATION 78(6):759-761 Bennett N; Cornely K Thalidomide makes a comeback: A case discussion exercise that integrates biochemistry and organic chemistry | 0 | 2 |
| 1863 | 22 | 32 | 1960 2001 JUN [15] JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Thalidomide dose proportionality assessment following single doses to healthy subjects | 3 | 4 |
| 1864 | 6 | 27 | 2013 2001 JUN [15] SYNTHESIS-STUTTGART (7):999-1000 Seijas JA; Vazquez-Tato MP; Gonzalez-Bande C; Martinez MM; Pacios-Lopez B Microwave promoted synthesis of a rehabilitated drug: Thalidomide | 0 | 2 |
| 1865 | 4 | 18 | 1824 2001 20010619-07:14:11 [JUN 19] BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 7(5):265-273 Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WF; Weisdorf DJ Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | 8 | 15 |
| 1866 | 3 | 4 | 1985 2001 JUN 21 NEW ENGLAND JOURNAL OF MEDICINE 344(25):1951-1952 Osman K; Comenzo R; Rajkumar SV Deep venous thrombosis and thalidomide therapy for multiple myeloma. | 44 | 57 |
| 1867 | 4 | 4 | 1886 2001 20010622-13:09:00 [JUN 22] BRITISH JOURNAL OF DERMATOLOGY 144(6):1292-1293 Passeron T; Lacour JP; Murr D; Ortonne JP Thalidomide-induced amenorrhoea: two cases | 4 | 4 |
| 1868 | 28 | 53 | 1955 2001 JUN 22 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387 Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity | 31 | 54 |
| 1869 | 9 | 18 | 1829 2001 JUL 1 BLOOD 98(1):210-216 Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 48 | 91 |
| 1870 | 22 | 30 | 1809 2001 JUL [15] ANNALS OF ONCOLOGY 12(7):885-886 Thomas DA; Kantarjian HM The revitalization of thalidomide | 4 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1871 | 6 | 16 | 1810 2001 JUL [15] ANNALS OF ONCOLOGY 12(7):987-990 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cineri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers | 16 | 26 |
| 1872 | 5 | 13 | 1811 2001 JUL [15] ANNALS OF ONCOLOGY 12(7):991-995 Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N Thalidomide and dexamethasone combination for refractory multiple myeloma | 29 | 40 |
| 1873 | 9 | 21 | 1830 2001 JUL 15 BLOOD 98(2):492-494 Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | 66 | 111 |
| 1874 | 2 | 4 | 1882 2001 JUL [15] BRITISH JOURNAL OF CANCER 85:25-25 Dalgleish A; Marriott J; Czajka A; Clarke I; Dredge K; Muller G; Stirling D New thalidomide analogues; Anti-cancer, anti-angiogenic and immunostimulatory. | 0 | 0 |
| 1875 | 12 | 22 | 1888 2001 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 114(1):78-83 Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia | 12 | 23 |
| 1876 | 1 | 3 | 1889 2001 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 114(1):245-245 Myers B; Grimley C; Dolan G Thalidomide and low-dose dexamethasone in myeloma treatment | 2 | 3 |
| 1877 | 8 | 17 | 1906 2001 JUL [15] CLINICAL CANCER RESEARCH 7(7):1888-1893 Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Kruger EA; Gubish E; Pluda JM; Reed E A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer | 23 | 58 |
| 1878 | 44 | 53 | 1925 2001 JUL [15] EXPERT OPINION ON BIOLOGICAL THERAPY 1(4):675-682 Marriott JB; Muller G; Stirling D; Dalgleish AG Immunotherapeutic and antitumour potential of thalidomide analogues | 11 | 15 |
| 1879 | 2 | 9 | 1940 2001 JUL [15] HAEMATOLOGICA 86(7):772-773 Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia | 7 | 11 |
| 1880 | 34 | 70 | 1990 2001 JUL [15] ONCOLOGY-NEW YORK 15(7):867-874 Rajkumar SV Current status of thalidomide in the treatment of cancer | 9 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1881 | 4 | 8 | 1991 2001 JUL [15] ONCOLOGY-NEW YORK 15(7):877-878 Govindarajan R Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
| 1882 | 2 | 8 | 1992 2001 JUL [15] ONCOLOGY-NEW YORK 15(7):878-879 Hwu WJ Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
| 1883 | 7 | 40 | 1995 2001 JUL-AUG [JUL 15] OPHTHALMOLOGICA 215(4):284-289 Kaven C; Spraul CW; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro | 2 | 7 |
| 1884 | 6 | 48 | 2004 2001 JUL [15] SEMINARS IN HEMATOLOGY 38(3):250-259 Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G Thalidomide in the management of multiple myeloma | 18 | 31 |
| 1885 | 0 | 0 | 1798 2001 AUG [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U653-U653 Shi JD; Xiao ZL; Marks M; Kamat C; Pokala V Development of thalidomide analogs as anti-angiogenic agents. | 0 | 0 |
| 1886 | 0 | 0 | 1799 2001 AUG [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U659-U659 Xiao ZL; Schaefer K; Li PK Solid phase synthesis of thalidomide and its analogs. | 0 | 0 |
| 1887 | 0 | 0 | 1800 2001 AUG [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U685-U685 Luzzio FA; Figg WD; Mayorov AV; Kruger EA Thalidomide metabolites and analogs, part 3: Synthesis and antiangiogenic activity of the teratogenic and TNF-alpha-modulatory thalidomide analog EM-12. | 0 | 0 |
| 1888 | 12 | 59 | 1831 2001 AUG 15 BLOOD 98(4):958-965 Raza A; Meyer P; Dutt D; Zorat F; Lisak L; Nascimben F; du Randt M; Kaspar C; Goldberg C; Loew J; Dar S; Gezer S; Venugopal P; Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes | 28 | 60 |
| 1889 | 8 | 38 | 1895 2001 AUG [15] BRITISH JOURNAL OF PHARMACOLOGY 133(8):1414-1423 Lienenluke B; Stojanovic T; Fiebig T; Fayyazi A; Germann T; Hecker M Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat-role of endothelial cell-leukocyte interaction | 3 | 4 |
| 1890 | 68 | 87 | 1924 2001 AUG [15] EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1891 | 54 | 68 | 1944 2001 AUG [15] HAUTARZT 52(8):726-733 Kuhn A; Hefter H; Ruzicka T; Lehmann P Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus | 0 | 0 |
| 1892 | 21 | 26 | 1958 2001 AUG 15 JOURNAL OF CLINICAL ONCOLOGY 19(16):3593-3595 Rajkumar SV; Kyle RA Thalidomide in the treatment of plasma cell malignancies | 6 | 7 |
| 1893 | 7 | 22 | 1959 2001 AUG 15 JOURNAL OF CLINICAL ONCOLOGY 19(16):3596-3601 Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P Treatment of Waldenstrom's macroglobulinemia with thalidomide | 16 | 27 |
| 1894 | 7 | 29 | 1967 2001 AUG [15] JOURNAL OF NEURO-ONCOLOGY 54(1):31-38 Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme | 13 | 20 |
| 1895 | 10 | 19 | 1975 2001 AUG [15] LEUKEMIA 15(8):1274-1276 Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide for previously untreated indolent or smoldering multiple myeloma | 28 | 43 |
| 1896 | 8 | 17 | 1976 2001 AUG [15] LEUKEMIA & LYMPHOMA 42(4):683-+ Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma | 8 | 9 |
| 1897 | 18 | 29 | 1980 2001 AUG [15] MUSCLE & NERVE 24(8):1050-1057 Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD Thalidomide neuropathy in patients treated for metastatic prostate cancer | 11 | 16 |
| 1898 | 13 | 21 | 1982 2001 AUG [15] NETHERLANDS JOURNAL OF MEDICINE 59(2):45-49 van de Poel MHW; Pasman PC; Schouten HC The use of thalidomide in chronic refractory graft versus host disease | 1 | 3 |
| 1899 | 14 | 41 | 2002 2001 AUG [15] RHEUMATOLOGY 40(8):933-938 Kari JA; Shah V; Dillon MJ Behcet's disease in UK children: clinical features and treatment including thalidomide | 5 | 14 |
| 1900 | 10 | 40 | 2005 2001 AUG [15] SEMINARS IN ONCOLOGY 28(4):62-66 Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | 15 | 37 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1901 | 0 | 0 | 1953 2001 AUG 22 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 286(8):909-909 Mitka M Thalidomide battles myeloma | 1 | 0 |
| 1902 | 3 | 5 | 1832 2001 SEP 1 BLOOD 98(5):1614-1615 Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy | 59 | 90 |
| 1903 | 1 | 1 | 1812 2001 SEP [15] ANNALS OF ONCOLOGY 12(9):1333-1333 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001) | 0 | 1 |
| 1904 | 0 | 0 | 1815 2001 SEP [15] ARTHRITIS AND RHEUMATISM 44(9):S125-S125 Barthel HR Successful treatment of Weber Christian disease (WCD) with thalidomide in a patient failing multiple other medical therapies | 0 | 0 |
| 1905 | 0 | 0 | 1816 2001 SEP [15] ARTHRITIS AND RHEUMATISM 44(9):S272-S272 Lehman TJ; Striegel KH; Onel KB Thalidomide therapy for corticosteroid dependent systemic onset juvenile rheumatoid arthritis | 0 | 1 |
| 1906 | 0 | 0 | 1817 2001 SEP [15] ARTHRITIS AND RHEUMATISM 44(9):S275-S275 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis (AS). | 0 | 2 |
| 1907 | 0 | 0 | 1818 2001 SEP [15] ARTHRITIS AND RHEUMATISM 44(9):S280-S280 Cuadrado MJ; Smith E; Gordon P; Karim Y; Khamashta MA; Hughes GRV Thalidomide: Efficacy and safety in 30 patients with lupus and skin involvement. | 0 | 0 |
| 1908 | 13 | 35 | 1907 2001 SEP [15] CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
| 1909 | 28 | 123 | 1912 2001 SEP [15] CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
| 1910 | 10 | 46 | 1922 2001 SEP [15] ELECTROPHORESIS 22(15):3185-3190 Schoetz G; Trapp O; Schurig V Determination of the enantiomerization barrier of thalidomide by dynamic capillary electrokinetic chromatography | 1 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1911 | 1 | 1 | 1931 2001 SEP [15] GASTROENTEROLOGY 121(3):747-747 Fox MR; Harris A Intractable insomnia after cessation of treatment with Thalidomide. (vol 120, pg 1567, 2001) | 0 | 0 |
| 1912 | 13 | 25 | 1952 2001 SEP [15] ISRAEL MEDICAL ASSOCIATION JOURNAL 3(9):644-648 Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R Amelioration of experimental colitis by thalidomide | 1 | 1 |
| 1913 | 10 | 27 | 1957 2001 SEP [15] JOURNAL OF CLINICAL IMMUNOLOGY 21(5):357-364 Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues | 3 | 3 |
| 1914 | 9 | 9 | 1962 2001 SEP [15] JOURNAL OF DERMATOLOGICAL TREATMENT 12(3):145-147 Thomson KF; Goodfield MJD Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus | 0 | 2 |
| 1915 | 8 | 27 | 1971 2001 SEP [15] JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 298(3):1221-1226 Drenth JPH; Vonk AG; Simon A; Powell R; Van der Meer JWM Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: A randomized, double-blind, placebo-controlled trial | 1 | 7 |
| 1916 | 24 | 55 | 1993 2001 SEP-OCT [SEP 15] OPHTHALMIC RESEARCH 33(5):256-263 Baatz H; Tonessen B; Prada J; Pleyer U Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis | 1 | 4 |
| 1917 | 26 | 48 | 1999 2001 SEP-OCT [SEP 15] QUIMICA NOVA 24(5):683-688 Lima LM; Fraga CAM; Barreiro EJ The rebirth of a drug: Thalidomide | 0 | 1 |
| 1918 | 16 | 37 | 1883 2001 SEP 28 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 18 | 30 |
| 1919 | 6 | 6 | 1819 2001 OCT [15] ARTHRITIS AND RHEUMATISM 44(10):2456-2457 Lee L; Lawford R; McNeil HP The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: comment on the letter by Breban et al | 2 | 5 |
| 1920 | 1 | 4 | 1820 2001 OCT [15] ARTHRITIS AND RHEUMATISM 44(10):2457-2458 Breban M; Dougados M The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: Reply | 2 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1921 | 3 | 23 | 1821 2001 OCT 15 BIOCHEMICAL PHARMACOLOGY 62(8):1081-1086 Onat D; Stahl W; Sies H Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344) | 2 | 3 |
| 1922 | 3 | 4 | 1890 2001 OCT [15] BRITISH JOURNAL OF HAEMATOLOGY 115(1):234-234 Myers B; Grimley C; Crouch D; Dolan G Lack of response to thalidomide in plasmacytomas | 2 | 4 |
| 1923 | 8 | 13 | 1918 2001 OCT [15] DRUG METABOLISM AND DISPOSITION 29(10):1355-1357 Teo SK; Harden JL; Burke AB; Noormohamed FH; Youle M; Johnson MA; Peters BS; Stirling DI; Thomas SD Thalidomide is distributed into human semen after oral dosing | 7 | 12 |
| 1924 | 8 | 10 | 1941 2001 OCT [15] HAEMATOLOGICA 86(10):1108-1109 Camba L; Peccatori J; Pescarollo A; Tresoldi M; Corradini P; Bregni M Thalidomide and thrombosis in patients with multiple myeloma | 10 | 11 |
| 1925 | 5 | 20 | 1942 2001 OCT [15] HAUTARZT 52:962-965 Hoch O; Muller S; Buttner G; Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 3 | 5 |
| 1926 | 5 | 15 | 1943 2001 OCT [15] HAUTARZT 52:966-969 Petering H; Kiehl P; Vogelbruch M; Sticht-Groh V; Kapp A; Werfel T Chemotherapy-induced erythema nodosum leprosum: successful treatment with thalidomide | 0 | 0 |
| 1927 | 0 | 0 | 1945 2001 OCT [15] HEPATOLOGY 34(4):279A-279A Muriel P; Fernandez-Martinez E; Perez-Alvarez VM; Morales-Rios MS A thalidomide analog with hepatoprotective and antifibrotic properties in biliary obstruction-induced cirrhosis in the rat. | 0 | 0 |
| 1928 | 0 | 0 | 1946 2001 OCT [15] HEPATOLOGY 34(4):516A-516A Muriel P; Ponce S; Garcia JC Thalidomide partially prevents CCl4-induced liver cirrhosis. | 0 | 0 |
| 1929 | 0 | 0 | 1947 2001 OCT [15] HEPATOLOGY 34(4):517A-517A Muriel P; Garcia JC; Ponce S; Perez-Alvarez VM; Fernandez-Martinez E; Morales-Rios MS Synthesis and pharmacological evaluation of a thalidomide analog, the 3-phthalimido-3-(3,4-dimethoxyphenyl)propanoic acid in liver cirrhosis induced by bile duct ligation in the rat. | 0 | 0 |
| 1930 | 13 | 18 | 1961 2001 OCT [15] JOURNAL OF CLINICAL PHARMACOLOGY 41(10):1091-1097 Aweeka F; Trapnell C; Chernoff M; Jayewardene A; Spritzler J; Bellibas SE; Lizak P; Jacobson J Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251 | 6 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1931 | 5 | 29 | 1968 2001 OCT [15] JOURNAL OF NEURO-ONCOLOGY 55(1):11-17 Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S Gliomatosis cerebri: Post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide | 0 | 4 |
| 1932 | 0 | 5 | 1973 2001 OCT [15] LANCET ONCOLOGY 2(10):634-635 Hwu WJ; Raizer J; Panageas KS; Lis E Treatment of metastatic melanoma in the brain with temozolomide and thalidomide | 3 | 5 |
| 1933 | 3 | 3 | 1986 2001 OCT 18 NEW ENGLAND JOURNAL OF MEDICINE 345(16):1214-1215 Kudva GC; Collins BT; Dunphy FR Thalidomide for malignant melanoma. | 1 | 2 |
| 1934 | 36 | 49 | 1914 2001 OCT 19 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1178-1182 Tuinmann G; Hegewisch-Becker S; Hossfeld DK New indications for thalidomide | 2 | 3 |
| 1935 | 4 | 26 | 1915 2001 OCT 19 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1183-1186 Maio G On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation | 0 | 3 |
| 1936 | 0 | 0 | 1903 2001 OCT 23 CIRCULATION 104(17):123-123 Yang E; Matcuk G; Zhang Y; Talbi S; Chen M; Ho M; Liao C; Tsao PS; Quertermous T; Deng D; Sampas N; Ach R; Love W Anti-angiogenic effects of thalidomide characterized by transciptional profiling of endothelial cell-specific gene expression | 0 | 0 |
| 1937 | 0 | 0 | 1904 2001 OCT 23 CIRCULATION 104(17):566-566 Kishan CV; Saucedo JF; Fahdi I; Gaddam V; Razek H; Bissett JK; Anaissie E; Barlogie B; Mehta JL High dose thalidomide is associated with symptomatic bradycardia | 0 | 0 |
| 1938 | 32 | 67 | 1896 2001 NOV 1 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 6 | 13 |
| 1939 | 10 | 15 | 1965 2001 NOV 1 JOURNAL OF INFECTIOUS DISEASES 184(9):1192-1196 Hanekom WA; Hughes J; Haslett PAJ; Apolles P; Ganiso V; Allin R; Goddard E; Hussey GD; Kaplan G The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children | 3 | 3 |
| 1940 | 3 | 5 | 1814 2001 NOV 12 ARCHIVES OF INTERNAL MEDICINE 161(20):2502-2503 Rajkumar SV; Fonseca R; Witzig TE Complete resolution of reflex sympathetic dystrophy with thalidomide treatment | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1941 | 8 | 12 | 1802 2001 NOV [15] AMERICAN JOURNAL OF GASTROENTEROLOGY 96(11):3207-3209 Raufman JP; Lamps LW Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C | 0 | 0 |
| 1942 | 65 | 116 | 1808 2001 NOV [15] ANNALS OF MEDICINE 33(8):516-525 Ginsburg PM; Dassopoulos T; Ehrenpreis ED Thalidomide treatment for refractory Crohn's disease: a review. of the history, pharmacological mechanisms and clinical literature | 9 | 13 |
| 1943 | 2 | 12 | 1891 2001 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 115(2):313-315 Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M Thalidomide in agnogenic and secondary myelofibrosis | 11 | 16 |
| 1944 | 3 | 8 | 1892 2001 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 115(2):484-485 Biagi JJ; Prince HM Thalidomide is effective for extramedullary relapse of multiple myeloma postallogeneic bone marrow transplantation | 1 | 1 |
| 1945 | 39 | 60 | 1900 2001 NOV [15] CELLULAR AND MOLECULAR BIOLOGY 47(7):1105-1114 Settles B; Stevenson A; Wilson K; Mack C; Ezell T; Davis MF; Taylor LD Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide | 7 | 10 |
| 1946 | 1 | 2 | 1901 2001 NOV [15] CHEMISTRY IN BRITAIN 37(11):38-40 Stephens T Reinventing thalidomide | 0 | 1 |
| 1947 | 8 | 25 | 1908 2001 NOV [15] CLINICAL CANCER RESEARCH 7(11):3311-3313 Onn A; Tseng JE; Herbst RS Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy | 1 | 10 |
| 1948 | 12 | 56 | 1909 2001 NOV [15] CLINICAL CANCER RESEARCH 7(11):3349-3355 Fujita J; Mestre JR; Zeldis JB; Subbaramaiah K; Dannenberg AJ Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 | 19 | 29 |
| 1949 | 0 | 0 | 1910 2001 NOV [15] CLINICAL CANCER RESEARCH 7(11):3666S-3667S Hsu C; Chen C; Chen L; Wu C; Hsieh F; Cheng A Use of thalidomide in the treatment of advanced hepatocellular carcinoma (HCC): With emphasis on using power Doppler sonography to evaluate the vascularity of the tumor and its correlation with tumor response. | 0 | 0 |
| 1950 | 1 | 1 | 1923 2001 NOV [15] EUROPEAN JOURNAL OF CANCER 37(16):1966-1966 [Anon] Thalidomide is back | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1951 | 16 | 24 | 1950 2001 NOV [15] INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 55(9):627-631 Diggle GE Thalidomide: 40 years on | 7 | 9 |
| 1952 | 0 | 0 | 1979 2001 NOV [15] MOLECULAR BIOLOGY OF THE CELL 12:23A-23A Ezell TN Apoptotic cell death induced by low doses of the tumor necrosis alpha inhibitor, thalidomide in human T leukemic cells | 0 | 0 |
| 1953 | 2 | 10 | 1997 2001 NOV-DEC [NOV 15] POLISH JOURNAL OF PHARMACOLOGY 53(6):709-713 Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M Influence of thalidomide on Bcl(2) expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients | 0 | 0 |
| 1954 | 0 | 0 | 2000 2001 NOV [15] RADIOLOGY 221:387-387 Faria SC; Charnsangavej C; Sawaf Y; Hess KR; Tamm EP; Lee T CT quantification of antiangiogenic effects of thalidomide | 0 | 0 |
| 1955 | 0 | 0 | 1833 2001 NOV 16 BLOOD 98(11):52B-52B Anders O; Plath F; Emmrich J; Freund M Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. | 0 | 0 |
| 1956 | 0 | 0 | 1834 2001 NOV 16 BLOOD 98(11):52B-52B Arkel YS; Ku DHW; Le P Effect of thalidomide on tissue factor activity in monocytic and endothelial cell lines, and relationship to tumor necrosis factor-alpha (TNF). | 0 | 0 |
| 1957 | 0 | 0 | 1835 2001 NOV 16 BLOOD 98(11):161A-162A Zangari M; Siegel E; Anaissie E; Saghafifar F; Morris C; Fink L; Barlogie B; Tricot G Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (pts) treated with thalidomide (Thal): The Arkansas experience. | 0 | 4 |
| 1958 | 0 | 0 | 1836 2001 NOV 16 BLOOD 98(11):162A-162A Palumbo A; Giaccone L; Bringhen S; Cavallo F; Falco P; Rus C; Bertola A; Pileri A; Boccadoro M Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. | 0 | 4 |
| 1959 | 0 | 0 | 1837 2001 NOV 16 BLOOD 98(11):162A-162A Wechalekar AD; Sutton D; Voralia M; Stewart AK; Chen CI Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. | 0 | 5 |
| 1960 | 0 | 0 | 1838 2001 NOV 16 BLOOD 98(11):162A-162A Kakimoto T; Hattori Y; Okamoto S; Sato N; Yamaguchi M; Morita K; Yamada T; Takayama N; Shimada N; Tanigawara Y; Ikeda Y Clinical significance of serial monitoring of plasma concentration of thalidomide and angiogenic growth factors in patients with refractory myeloma. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1961 | 0 | 0 | 1839 2001 NOV 16 BLOOD 98(11):162A-163A Rajkumar SV; Dispenzieri A; Lacy M; Geyer S; Iturria N; Fonseca R; Hayman SR; Lust JA; Kyle R; Greipp PR; Gertz MA; Witzig TE Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM). | 0 | 4 |
| 1962 | 0 | 0 | 1840 2001 NOV 16 BLOOD 98(11):163A-163A Tosi P; Zamagni E; Cellini C; Cangini D; Tura S; Baccarani M; Cavo M Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractor multiple myeloma. | 0 | 3 |
| 1963 | 0 | 0 | 1841 2001 NOV 16 BLOOD 98(11):163A-163A Alexanian R; Weber DM; Giralt S; Delasalle KB Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. | 0 | 2 |
| 1964 | 0 | 0 | 1842 2001 NOV 16 BLOOD 98(11):163A-163A Grosbois B; Bellissant E; Moreau P; Attal M; Zerbib R Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. | 0 | 5 |
| 1965 | 0 | 0 | 1843 2001 NOV 16 BLOOD 98(11):163A-163A Durie BGM; Stepan DE Low dose thalidomide alone and in combination: Long term follow-up. | 0 | 6 |
| 1966 | 0 | 0 | 1844 2001 NOV 16 BLOOD 98(11):163A-163A Neben K; Moehler TM; Benner A; Kraemer A; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM). | 0 | 0 |
| 1967 | 0 | 0 | 1845 2001 NOV 16 BLOOD 98(11):164A-164A Dimopoulos M; Panayiotidis P; Grigoraki V; Poziopoulos C; Xilouri I; Kiamouris C; Tassidou A; Gika D; Stefanoudaki K; Anagnostopoulos N; Anagnostou D Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. | 0 | 7 |
| 1968 | 0 | 0 | 1846 2001 NOV 16 BLOOD 98(11):164A-164A Seldin DC; Choufani E; Skinner M; Wright DG; Dember L; Weisman J; Fennessey S; Finn K; Sanchorawala V A phase I/II trial of thalidomide for patients with AL amyloidosis. | 0 | 1 |
| 1969 | 0 | 0 | 1847 2001 NOV 16 BLOOD 98(11):182B-182B Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Yalcin A Terminal differentiation and apoptosis of myeloid leukemia induced by thalidomide and rhGM-CSF combination. | 0 | 0 |
| 1970 | 0 | 0 | 1848 2001 NOV 16 BLOOD 98(11):215B-215B Manson SD; Venugopal P; Gregory SA; Raza A; Sivaraman S; Preisler H Treatment of relapsed/refractory acute myeloid leukemia (AML) with thalidomide as a single agent: Clinical and biologic responses. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1971 | 0 | 0 | 1849 2001 NOV 16 BLOOD 98(11):222B-222B Sivaraman S; Venugopal P; Hu WY; Gladstone B; Galili N; Nair A; Manjali J; Mogongwa A; Zhao HP; Manson S; Preisler H Effect of thalidomide as a single agent on serum cytokine levels in patients with relapsed acute myeloid leukemia. | 0 | 0 |
| 1972 | 0 | 0 | 1850 2001 NOV 16 BLOOD 98(11):246B-246B Pro B; Younes A; Albitar M; Hagemeister FB; Rodriguez MA; McLaughlin P; Clemons M; Samaniego F; Cabanillas F Phase II study of thalidomide in patients with recurrent Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL). | 0 | 0 |
| 1973 | 0 | 0 | 1851 2001 NOV 16 BLOOD 98(11):271B-271B Fabbri A; Biscardi M; Innocenti F; Balestri F; Gavazzi S; Bellesi G; Grossi A Thalidomide in combination with amifostine in the treatment of MDS: Evaluation of clinical and laboratory findings. | 0 | 0 |
| 1974 | 0 | 0 | 1852 2001 NOV 16 BLOOD 98(11):273B-273B Raza A; Lisak L; Dutt D; Dean L; Fantroy L; Syed E; Gezer S; Hsu WT; Goldberg C; Loew J; Venugopal P Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). | 0 | 0 |
| 1975 | 0 | 0 | 1853 2001 NOV 16 BLOOD 98(11):273B-274B Raza A; Dutt D; Lisak L; Dean L; Fantroy L; Gezer S; Syed E; Goldberg C; Loew J; Hsu WT; Venugopal P Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS). | 0 | 0 |
| 1976 | 0 | 0 | 1854 2001 NOV 16 BLOOD 98(11):296B-297B Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M; Domanski D Influence of thalidomide on bcl-2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow lymphocyte subsets of multiple myeloma patients. | 0 | 0 |
| 1977 | 0 | 0 | 1855 2001 NOV 16 BLOOD 98(11):307B-307B Alegre A; Macias GR; Granda A; Golbano N; Martinez E; Alaez C; Blazquez C; Gongora E; Cannata J; Sanchez-Godoy P; Martinez-Chamorro C; Arranz R; de Soria VGG; Figuera A; Arranz E; Fernandez-Ranada JM Thalidomide as rescue treatment of relapses after haematopoietic transplantation in multiple myeloma. | 0 | 0 |
| 1978 | 0 | 0 | 1856 2001 NOV 16 BLOOD 98(11):307B-307B Ahmad I; Alam AR; Hahn T; Becker J; Chanan-Khan AA; Czuczman M; Bernstein S; Bernstein Z; McCarthy P Thalidomide plus VAD (vincristine, doxorabicin and dexamethasone) salvage therapy for VAD-refractory multiple myeloma, prior to autologous peripheral blood stem cell transplant (PBSCT). | 0 | 0 |
| 1979 | 0 | 0 | 1857 2001 NOV 16 BLOOD 98(11):307B-307B Bibas M; Andriani A; Ferrari A; Montanaro M; Niscola G; Recine U; Chierichini A Thalidomide treatment for relapsed/refractory multiple myeloma: A retrospective multicenter study. | 0 | 0 |
| 1980 | 0 | 0 | 1858 2001 NOV 16 BLOOD 98(11):308B-308B Grosbois B; Bellissant E; Muret E; Voillat L; Zerbib R Measurement of seric thalidomide (Thal) level in patients treated for advanced multiple myeloma (MM). | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1981 | 0 | 0 | 1859 2001 NOV 16 BLOOD 98(11):309B-309B Kasper B; Moehler TM; Neben K; Ho AD; Goldschmidt H Response to a combination therapy of thalidomide and Pegintron (R) in patients with progressive multiple myeloma (MM). | 0 | 1 |
| 1982 | 0 | 0 | 1860 2001 NOV 16 BLOOD 98(11):310B-310B Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: Implications for multiple myeloma therapy. | 0 | 0 |
| 1983 | 0 | 0 | 1861 2001 NOV 16 BLOOD 98(11):311B-311B Avalos JS; Barazzutti L; Korin J; Kusminsky G; Ferro H; Tavella O; Foncuberta M; Tartas N Thalidomide and cranial nerves neuropathies. | 0 | 0 |
| 1984 | 0 | 0 | 1862 2001 NOV 16 BLOOD 98(11):311B-311B Offidani M; Mele A; Marconi M; Corvatta L; Candela M; Pieroni S; Malerba L; Rupoli S; Olivieri A; Leoni P Thalidomide plus melphalan in relapsed-refractory multiple myeloma. | 0 | 1 |
| 1985 | 0 | 0 | 1863 2001 NOV 16 BLOOD 98(11):313B-313B Womeldorph JL; Myhand RC; Monahan BP Reversible acute renal failure following initiation of thalidomide therapy in a patient with relapsed multiple myeloma. | 0 | 0 |
| 1986 | 0 | 0 | 1864 2001 NOV 16 BLOOD 98(11):351A-352A Alvi S; Shaher A; Shaikh M; Anthwal S; Siddiqi F; Akhtar A; Ashraf H; Meagher R; Mundle S; Shetty V; Goldberg C; Galili N; Borok RZ; Raza A MDS patients with hematological response to thalidomide show enhanced in vitro growth potential. | 0 | 0 |
| 1987 | 0 | 0 | 1865 2001 NOV 16 BLOOD 98(11):352A-352A Alvi S; Shaikh M; Anthwal S; Shaher A; Tamoseviciene D; Novick A; Reddy P; Allampallam K; Hsu WT; Galili N; Borok RZ; Raza A Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide. | 0 | 0 |
| 1988 | 0 | 0 | 1866 2001 NOV 16 BLOOD 98(11):353A-354A Baker AF; Bellamy WT; Glinsmann-Gibson BJ; Heaton R; Buresh A; Grogan TM; List AF Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): Evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. | 0 | 0 |
| 1989 | 0 | 0 | 1867 2001 NOV 16 BLOOD 98(11):365B-365B Game M; Coso D; Sturgeon J; Crump M; Keating A Thalidomide and low dose vinblastine as palliative therapy for patients relapsing after autotransplant for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). | 0 | 1 |
| 1990 | 0 | 0 | 1868 2001 NOV 16 BLOOD 98(11):373A-374A Uziel O; Shapira A; Radnay J; Lahav M; Lishner M Thalidomide downregulates transcript levels of GC-rich promoter genes in multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1991 | 0 | 0 | 1869 2001 NOV 16 BLOOD 98(11):395B-395B Moehler TM; Neben K; Kasper B; Kordelas L; Egerer G; Goerner M; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as remission induction regimen for poor prognosis multiple myeloma patients before autologous or allogeneic stem cell transplantation. | 0 | 0 |
| 1992 | 0 | 0 | 1870 2001 NOV 16 BLOOD 98(11):622A-622A Musto P; Falcone A; Bodenizza C; Sanpaolo G; Matera R; Bisceglia M; Carella AM Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with myelodysplastic syndromes (MDS): Relationship to serum and marrow levels of angiogenetic growth factors (AGF). | 0 | 3 |
| 1993 | 0 | 0 | 1871 2001 NOV 16 BLOOD 98(11):627A-627A Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt R; Geyer GM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia (MMM). | 0 | 1 |
| 1994 | 0 | 0 | 1872 2001 NOV 16 BLOOD 98(11):685A-685A Somlo G; Yamamoto N; Sarah C; O'Donnell M; Snyder D; Sahebi F; Kogut N; Spielberger R; Molina A; Parker P; Popplewell L; Fung H; Rodriguez R; Stein A; Krishnan A; Chow W; Lopez F; Forman S Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon alpha-2 (IF) with, or without thalidomide (Thal) for multiple myeloma. High complete response rate and moderate toxicities. | 0 | 1 |
| 1995 | 0 | 0 | 1873 2001 NOV 16 BLOOD 98(11):775A-775A Mitsiades N; Mitsiades CS; Poulaki V; Akiyama M; Tai YT; Lin BK; Hayashi T; Catley L; Hideshima T; Chauhan D; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications. | 0 | 1 |
| 1996 | 0 | 0 | 1874 2001 NOV 16 BLOOD 98(11):775A-775A Richardson PG; Schlossman RL; Hideshima T; Davies F; LeBlanc R; Catley L; Doss D; Kelly KA; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo J; Chauhan D; Munshi N; Weller E; Thomas S; Zeldis J; Anderson KC A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). | 0 | 10 |
| 1997 | 0 | 0 | 1875 2001 NOV 16 BLOOD 98(11):849A-849A Rajkumar SV; Hayman SR; Gertz MA; Dispenzieri A; Lacy M; Greipp PR; Geyer S; Itturia N; Fonseca R; Lust JA; Kyle R; Witzig TE Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). | 0 | 5 |
| 1998 | 0 | 0 | 1876 2001 NOV 16 BLOOD 98(11):849A-849A Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Goldschmidt H Genetic polymorphism in the tumor necrosis factor-alpha locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma (MM). | 0 | 1 |
| 1999 | 0 | 0 | 1877 2001 NOV 16 BLOOD 98(11):863A-863A Bennett CL; Schumok GT; Kwaan HC; Raisch DW High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered. | 0 | 3 |
| 2000 | 115 | 191 | 1823 2001 20011127-04:23:06 [NOV 27] BIODRUGS 15(10):681-703 Meierhofer C; Dunzendorfer S; Wiedermann CJ Theoretical basis for the activity of thalidomide | 6 | 12 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2001 | 0 | 0 | 1927 2001 20011129-03:40:35 [NOV 29] FREE RADICAL BIOLOGY AND MEDICINE 31:S54-S54 Hansen JM; Gong SG; Harris C Thalidomide (TD) depletes glutathione and alters gene expression in the developing limb. | 0 | 0 |
| 2002 | 3 | 19 | 1878 2001 DEC 15 BLOOD 98(13):3846-3848 Moehler TM; Neben K; Benner A; Egerer G; Krasniqi F; Ho AD; Goldschmidt H Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy | 13 | 21 |
| 2003 | 10 | 38 | 1881 2001 DEC [15] BONE MARROW TRANSPLANTATION 28(12):1145-1150 Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation | 3 | 5 |
| 2004 | 3 | 12 | 1893 2001 DEC [15] BRITISH JOURNAL OF HAEMATOLOGY 115(3):605-608 Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion | 19 | 29 |
| 2005 | 8 | 53 | 1894 2001 DEC [15] BRITISH JOURNAL OF HAEMATOLOGY 115(4):881-894 Zorat F; Shetty V; Dutt D; Lisak L; Nascimben F; Allampallam K; Dar S; York A; Gezer S; Venugopal P; Raza A The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes | 13 | 22 |
| 2006 | 18 | 63 | 1917 2001 DEC [15] DRUG DEVELOPMENT RESEARCH 54(4):209-218 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat | 1 | 2 |
| 2007 | 37 | 44 | 1954 2001 DEC [15] JOINT BONE SPINE 68(6):582-587 Combe B Thalidomide: new indications? | 1 | 3 |
| 2008 | 6 | 6 | 1972 2001 DEC [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 45(6):965-966 George SJ; Hsu S Lichen planopilaris treated with thalidomide | 2 | 5 |
| 2009 | 8 | 18 | 2006 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):577-582 Barlogie B; Tricot G; Anaissie E Thalidomide in the management of multiple myeloma | 10 | 17 |
| 2010 | 7 | 21 | 2007 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):583-587 Kyle RA; Rajkumar SV Therapeutic application of thalidomide in multiple myeloma | 5 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2011 | 6 | 18 | 2008 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):588-592 Blade J; Esteve J; Rosinol L; Perales M; Montoto S; Tuset M; Montserrat E Thalidomide in refractory and relapsing multiple myeloma | 11 | 13 |
| 2012 | 12 | 25 | 2009 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):593-596 Desikan RK; Jagannath S Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions | 2 | 2 |
| 2013 | 22 | 47 | 2010 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):597-601 D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma | 0 | 10 |
| 2014 | 16 | 17 | 2011 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):602-606 Stirling D Thalidomide: A novel template for anticancer drugs | 7 | 12 |
| 2015 | 6 | 20 | 2219 2002 JAN 1 JOURNAL OF CLINICAL ONCOLOGY 20(1):302-306 Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M Phase II trial of thalidomide for patients with advanced renal cell carcinoma | 20 | 34 |
| 2016 | 4 | 5 | 2153 2002 20030108-18:15:13 [JAN 08] CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS 973:414-418 Jin SH; Il Kim T; Han DS; Shin SK; Kim WH Thalidomide suppresses the interleukin 1 beta-induced NF kappa B signaling pathway in colon cancer cells | 1 | 2 |
| 2017 | 9 | 23 | 2267 2002 20030114-02:36:42 [JAN 14] MEDICAL ONCOLOGY 19(4):219-226 Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma | 1 | 2 |
| 2018 | 13 | 14 | 2179 2002 JAN-FEB [JAN 15] EUROPEAN JOURNAL OF DERMATOLOGY 12(1):63-65 Frances C; El Khoury S; Gompel A; Becherel PA; Chosidow O; Piette JC Transient secondary amenorrhea in women treated by thalidomide | 1 | 2 |
| 2019 | 7 | 20 | 2240 2002 JAN [15] JOURNAL OF PEDIATRICS 140(1):125-127 Lehman TJA; Striegel KH; Onel KB Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis | 4 | 7 |
| 2020 | 4 | 40 | 2241 2002 JAN 15 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 27(3-4):497-505 Trapp O; Schoetz G; Schurig V Stereointegrity of thalidomide: gas-chromatographic determination of the enantiomerization barrier | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2021 | 7 | 22 | 2253 2002 JAN [15] LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 14 | 25 |
| 2022 | 5 | 24 | 2255 2002 JAN [15] LEUKEMIA & LYMPHOMA 43(1):133-137 Strupp C; Aivado M; Germing U; Gattermann N; Haas R Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports | 1 | 4 |
| 2023 | 4 | 11 | 2271 2002 JAN [15] OBSTETRICS AND GYNECOLOGY 99(1):125-128 Ances BM New concerns about thalidomide | 1 | 3 |
| 2024 | 1 | 1 | 2272 2002 JAN [15] ONCOLOGY-NEW YORK 16(1):21-22 Kurstin R Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease | 1 | 1 |
| 2025 | 19 | 28 | 2273 2002 JAN [15] ONCOLOGY-NEW YORK 16(1):22-24 Richardson P; Anderson K Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease - Drs. Paul Richardson and Kenneth Anderson respond | 0 | 0 |
| 2026 | 7 | 24 | 2279 2002 JAN [15] PHARMACEUTICAL RESEARCH 19(1):13-19 Goosen C; Laing TJ; du Plessis J; Goosen TC; Flynn GL Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs | 4 | 4 |
| 2027 | 19 | 36 | 2053 2002 FEB 1 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 10 | 24 |
| 2028 | 18 | 24 | 2216 2002 FEB 5 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151 Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry | 3 | 4 |
| 2029 | 12 | 26 | 2042 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):1-3 Mathe G Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system | 0 | 0 |
| 2030 | 54 | 61 | 2043 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 16 | 20 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2031 | 20 | 42 | 2044 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):13-19 Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M-leprae-induced TNF alpha production in vitro | 5 | 6 |
| 2032 | 15 | 82 | 2045 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30 Zorat F; Pozzato G Thalidomide in myelodysplastic syndromes | 3 | 3 |
| 2033 | 19 | 48 | 2046 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35 Shek LPC; Lim DLC Thalidomide in Behcet's disease | 7 | 10 |
| 2034 | 0 | 0 | 2167 2002 FEB [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 71(2):P83-P83 Lakhani N; Gordon S; Figg W; Dionne R Absorption and adverse effects of topical thalidomide. | 0 | 0 |
| 2035 | 0 | 0 | 2187 2002 FEB [15] FERTILITY AND STERILITY 77(2):S28-S28 Zhong S; Shen K; Lang J The effects of thalidomide on interleukin-6 and vascular endothelial growth factor expression of endometrial stromal cell in vitro. | 0 | 0 |
| 2036 | 13 | 36 | 2194 2002 FEB [15] GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
| 2037 | 1 | 8 | 2201 2002 FEB [15] HAUTARZT 53(2):150-150 Ochsendorf F; Kaufman R Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 0 | 0 |
| 2038 | 2 | 2 | 2202 2002 FEB [15] HAUTARZT 53(2):150-151 Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis - Statement | 0 | 0 |
| 2039 | 2 | 4 | 2220 2002 FEB 15 JOURNAL OF CLINICAL ONCOLOGY 20(4):1147-1149 Abramson N; Stokes PK; Luke M; Marks AR; Harris JM Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide | 0 | 3 |
| 2040 | 14 | 25 | 2228 2002 FEB [15] JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2041 | 7 | 8 | 2256 2002 FEB [15] LEUKEMIA & LYMPHOMA 43(2):351-354 Johnston RE; Abdalla SH Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia | 7 | 9 |
| 2042 | 4 | 26 | 2257 2002 FEB [15] LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
| 2043 | 27 | 34 | 2290 2002 FEB [15] THERAPEUTIC DRUG MONITORING 24(1):104-110 Price DK; Ando Y; Kruger EA; Weiss M; Figg WD 5 '-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis | 9 | 10 |
| 2044 | 4 | 4 | 2221 2002 MAR 1 JOURNAL OF CLINICAL ONCOLOGY 20(5):1429-1430 Nathan PD; Gore ME; Eisen TG Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma | 7 | 11 |
| 2045 | 27 | 34 | 2033 2002 MAR [15] ANNALS OF PHARMACOTHERAPY 36(3):521-525 Bessmertny O; Pham T Thalidomide use in pediatric patients | 1 | 2 |
| 2046 | 30 | 91 | 2049 2002 MAR [15] BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479 Hashimoto Y Structural development of biological response modifiers based on thalidomide | 7 | 14 |
| 2047 | 0 | 0 | 2127 2002 MAR [15] BONE MARROW TRANSPLANTATION 29:S100-S100 Mohty M; Stoppa A; Blaise D; Isnardon D; Gastaut J; Olive D; Gaugler B Differential regulation of dendritic cell function by the Immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 2048 | 0 | 0 | 2128 2002 MAR [15] BONE MARROW TRANSPLANTATION 29:S104-S104 Patriarca F; Fill C; Sperotto A; Damiani D; Zaja F; Cerno M; Fanin R Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients | 0 | 0 |
| 2049 | 0 | 0 | 2129 2002 MAR [15] BONE MARROW TRANSPLANTATION 29:S255-S256 Dagan L; Ovadia R; Taou D; Bar L The introduction of thalidomide (T) in BMT programs for patients with multiple myeloma (MM): encouraging results and a challenge for nursing team | 0 | 0 |
| 2050 | 12 | 49 | 2165 2002 MAR [15] CLINICAL IMMUNOLOGY 102(3):225-236 Oliver SJ; Kikuchi T; Krueger JG; Kaplan G Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement | 4 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2051 | 18 | 23 | 2195 2002 MAR [15] HAEMATOLOGICA 87(3):233-234 Tosi P; Cavo M Thalidomide in multiple myeloma: state of art | 3 | 4 |
| 2052 | 4 | 7 | 2196 2002 MAR [15] HAEMATOLOGICA 87(3):327-328 Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M Advantages of using thalidomide for the management of patients with refractory myeloma | 3 | 4 |
| 2053 | 13 | 21 | 2227 2002 MAR-APR [MAR 15] JOURNAL OF COMBINATORIAL CHEMISTRY 4(2):149-153 Xiao ZL; Schaefer K; Firestine S; Li PK Solid-phase synthesis of thalidomide and its analogues | 0 | 4 |
| 2054 | 12 | 18 | 2229 2002 MAR [15] JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(3):233-235 Selby W Thalidomide in inflammatory bowel disease: Too little, too soon | 0 | 0 |
| 2055 | 37 | 67 | 2230 2002 MAR 15 JOURNAL OF IMMUNOLOGY 168(6):2644-2651 Majumdar S; Lamothe B; Aggarwal BB Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester | 12 | 24 |
| 2056 | 15 | 40 | 2243 2002 MAR [15] JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 300(3):768-776 Hansen JM; Harris KK; Philbert MA; Harris C Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb | 2 | 5 |
| 2057 | 1 | 4 | 2274 2002 MAR [15] ONCOLOGY-NEW YORK 16(3):276-+ Phuphanich S Recurrent multicentric glioblastoma multiforme responds to thalidomide and chemotherapy | 0 | 0 |
| 2058 | 5 | 25 | 2284 2002 MAR [15] RADIOLOGE 42(3):222-230 Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Modder U Dynamic contrast-enhanced MRI for the evaluation of bone marrow microcirculation in hematologic malignancies before and during thalidomide therapy | 0 | 0 |
| 2059 | 0 | 0 | 2174 2002 20030325-03:44:42 [MAR 25] DRUG METABOLISM REVIEWS 34:148-148 Zhou SF; Li Y; Kestell P; Paxton JW Preliminary study of thalidomide transport by the human intestinal cell line Caco-2 | 0 | 0 |
| 2060 | 70 | 112 | 2034 2002 20020329-01:42:11 [MAR 29] ANNUAL REVIEW OF MEDICINE 53:629-657 Richardson P; Hideshima T; Anderson K Thalidomide: Emerging role in cancer medicine | 21 | 34 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2061 | 6 | 16 | 2025 2002 APR 1 AMERICAN JOURNAL OF MEDICINE 112(5):412-413 Badros AZ; Siegel E; Bodenner D; Zangari M; Zeldis J; Barlogie B; Tricot G Hypothyroidism in patients with multiple myeloma following treatment with thalidomide | 8 | 9 |
| 2062 | 8 | 30 | 2051 2002 APR 8 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 12(7):1043-1046 Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y Thalidomide and its analogues as cyclooxygenase inhibitors | 9 | 11 |
| 2063 | 6 | 6 | 2172 2002 APR 12 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 127(15):818-818 Mensing H New indication for thalidomide? | 0 | 0 |
| 2064 | 8 | 23 | 2182 2002 20030414-19:22:57 [APR 14] EUROPEAN JOURNAL OF SURGERY 168(11):641-645 Mall JW; Schwenk W; Philipp AW; Muller JM; Pollmann C Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits | 0 | 0 |
| 2065 | 17 | 24 | 2018 2002 APR [15] AKTUELLE NEUROLOGIE 29(3):149-152 Vogt T; Nill M; Hundsberger T Thalidomide neuropathy | 0 | 0 |
| 2066 | 0 | 21 | 2028 2002 APR [15] ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 88(4):421-424 Medeiros M; Araujo MI; Guimaraes NS; Freitas LAR; Silva TMC; Carvalho EM Therapeutic response to thalidomide in Melkersson-Rosenthal syndrome: a case report | 1 | 2 |
| 2067 | 11 | 19 | 2052 2002 APR [15] BJU INTERNATIONAL 89(6):591-595 Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide | 1 | 4 |
| 2068 | 9 | 19 | 2130 2002 APR [15] BONE MARROW TRANSPLANTATION 29(7):577-580 Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 6 | 7 |
| 2069 | 0 | 0 | 2189 2002 APR [15] GASTROENTEROLOGY 122(4):A194-A194 Bauditz J; Wedel S; Lochs H Thalidomide for treatment of intestinal bleeding: Correlation to VEGF | 1 | 1 |
| 2070 | 0 | 0 | 2190 2002 APR [15] GASTROENTEROLOGY 122(4):A395-A395 Kim JW; Kim SG; Kim HD; Kim CG; Kim BG; Kim JS; Jung HC; Song IS Effect of DA-6034 and thalidomide on trinitrobenzene sulfonic acid-induced murine ileitis | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2071 | 0 | 0 | 2191 2002 APR [15] GASTROENTEROLOGY 122(4):A498-A498 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 0 | 0 |
| 2072 | 0 | 0 | 2193 2002 APR [15] GUT 50:A4-A4 Khan ZH; Simpson E; Cole AT; Macdonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: The effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study | 1 | 1 |
| 2073 | 13 | 20 | 2197 2002 APR [15] HAEMATOLOGICA 87(4):344-345 Ribatti D; Vacca A Is thalidomide a true anti-angiogenic molecule in multiple myeloma? | 1 | 1 |
| 2074 | 14 | 22 | 2198 2002 APR [15] HAEMATOLOGICA 87(4):345-346 [Anon] Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders | 0 | 0 |
| 2075 | 15 | 35 | 2199 2002 APR [15] HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 28 |
| 2076 | 28 | 44 | 2208 2002 APR [15] INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 83(2):99-104 Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma | 1 | 3 |
| 2077 | 41 | 67 | 2215 2002 APR-JUN [APR 15] JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6(2):160-174 Kumar S; Witzig TE; Rajkumar SV Thalidomide as an anti-cancer agent | 6 | 10 |
| 2078 | 4 | 5 | 2222 2002 APR 15 JOURNAL OF CLINICAL ONCOLOGY 20(8):2212-2212 Cany L; Fitoussi O; Boiron JM; Marit G Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma | 4 | 4 |
| 2079 | 4 | 17 | 2275 2002 APR [15] ONCOLOGY-NEW YORK 16(4):23-26 Govindarajan R Irinoteean/Thalidomide in metastatic colorectal cancer | 4 | 5 |
| 2080 | 3 | 21 | 2280 2002 APR [15] PHARMACEUTICAL RESEARCH 19(4):434-439 Goosen C; Laing TJ; du Plessis J; Goosen TC; Lu GW; Flynn GL Percutaneous delivery of thalidomide and its N-alkyl analogs | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2081 | 3 | 83 | 2288 2002 APR [15] SOCIAL HISTORY OF MEDICINE 15(1):137-158 Daemmrich A A tale of two experts: Thalidomide and political engagement in the United States and West Germany | 0 | 0 |
| 2082 | 18 | 38 | 2262 2002 20020423-01:31:50 [APR 23] LUPUS 11(2):67-70 Piette JC; Sbai A; Frances C Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus | 3 | 5 |
| 2083 | 13 | 15 | 2232 2002 MAY 1 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363 Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267 | 5 | 5 |
| 2084 | 1 | 3 | 2029 2002 MAY 7 ANNALS OF INTERNAL MEDICINE 136(9):711-711 Escudier B; Lassau N; Leborgne S; Angevin E; Laplanche A Thalidomide and venous thrombosis | 5 | 8 |
| 2085 | 39 | 71 | 2041 2002 MAY [15] BIOLOGICAL & PHARMACEUTICAL BULLETIN 25(5):597-604 Marks MG; Shi JD; Fry MO; Xiao ZL; Trzyna M; Pokala V; Ihnat MA; Li PK Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation | 6 | 9 |
| 2086 | 56 | 93 | 2047 2002 MAY [15] BIOMEDICINE & PHARMACOTHERAPY 56(3):115-128 Richardson P; Hideshima T; Anderson K Thalidomide in multiple myeloma | 5 | 6 |
| 2087 | 12 | 36 | 2136 2002 MAY [15] BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 12 | 21 |
| 2088 | 23 | 42 | 2231 2002 MAY 15 JOURNAL OF IMMUNOLOGY 168(10):4914-4919 Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | 13 | 28 |
| 2089 | 0 | 0 | 2237 2002 MAY [15] JOURNAL OF NUCLEAR MEDICINE 43(5):267P-267P Kinuya S; Yokoyama K; Li XF; Bai J; Michigishi T; Tonami N Radioimmunotherapy with I-131-monoclonal antibody and antiangiogenic therapy with thalidomide in colon cancer xenografts. | 0 | 0 |
| 2090 | 110 | 164 | 2176 2002 20020521-02:50:07 [MAY 21] DRUGS & AGING 19(2):85-100 Zhou SF; Kestell P; Tingle MD; Paxton JW Thalidomide in cancer treatment - A potential role in the elderly? | 4 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2091 | 61 | 82 | 2168 2002 20030526-16:40:42 [MAY 26] CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
| 2092 | 5 | 5 | 2054 2002 JUN 1 BLOOD 99(11):4247-4248 Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J Thromboembolic events during treatment with thalidomide | 12 | 17 |
| 2093 | 4 | 4 | 2055 2002 JUN 1 BLOOD 99(11):4248-4248 Lee FC Second response to lower-dose thalidomide in a patient with multiple myeloma | 2 | 2 |
| 2094 | 3 | 6 | 2056 2002 JUN 1 BLOOD 99(11):4249-4249 Zangari M Thalidomide and thromboembolism - Response | 0 | 0 |
| 2095 | 22 | 24 | 2223 2002 JUN 1 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609 Eisen T Thalidomide in solid malignancies | 6 | 12 |
| 2096 | 6 | 26 | 2224 2002 JUN 1 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial | 10 | 18 |
| 2097 | 21 | 36 | 2019 2002 JUN [15] ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(6):1117-1124 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 4 | 14 |
| 2098 | 9 | 36 | 2035 2002 JUN [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(6):1887-1895 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis | 3 | 5 |
| 2099 | 8 | 14 | 2038 2002 JUN 15 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 47(3):249-254 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY One-year open-label trial of thalidomide in ankylosing spondylitis | 3 | 9 |
| 2100 | 32 | 45 | 2048 2002 JUN [15] BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199 Ng SSW; Brown M; Figg WD Thalidomide, an antiangiogenic agent with clinical activity in cancer | 5 | 6 |
Page 7: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22